Overview

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Status:
Not yet recruiting

Trial end date:
2025-04-25

Target enrollment:

Participant gender:

Summary

To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received treatment.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Loxo Oncology, Inc.
The Leukemia and Lymphoma Society

Treatments:

Allopurinol
Obinutuzumab
Valacyclovir
Venetoclax